Table 1 Patients’ demographics, clinical characteristics at diagnosis
Variables | Total (%) | Cause-specific Death (%) | Death due to other causes (%) | P Value |
|---|---|---|---|---|
n | 2813 | 398 | 268 | |
Age | < 0.0001 | |||
< 50 | 309 (10.98%) | 32 (8.04%) | 4 (1.49%) | |
50–59 | 643 (22.86%) | 64 (16.08%) | 24 (8.96%) | |
60–69 | 711 (25.28%) | 96 (24.12%) | 39 (14.55%) | |
≥ 70 | 1150 (40.88%) | 206 (51.76%) | 201 (75%) | |
Race | 0.375 | |||
White | 2265 (80.52%) | 319 (80.15%) | 222 (82.84%) | |
Black | 318 (11.3%) | 59 (14.82%) | 30 (11.19%) | |
Other | 230 (8.18%) | 20 (5.03%) | 16 (5.97%) | |
Sex | 0.8802 | |||
Male | 1466 (52.12%) | 210 (52.76%) | 143 (53.36%) | |
Female | 1347 (47.88%) | 188 (47.24%) | 125 (46.64%) | |
Pathology Grade | 0.013 | |||
I | 492 (17.49%) | 49 (12.31%) | 38 (14.18%) | |
II | 2037 (72.41%) | 273 (68.59%) | 203 (75.75%) | |
III | 220 (7.82%) | 58 (14.57%) | 23 (8.58%) | |
IV | 64 (2.28%) | 18 (4.52%) | 4 (1.49%) | |
Lymph node metastasis | < 0.0001 | |||
NO | 1993 (70.85%) | 195 (48.99%) | 202 (75.37%) | |
Yes | 758 (26.95%) | 181 (45.48%) | 55 (20.52%) | |
NX | 62 (2.2%) | 22 (5.53%) | 11 (4.1%) | |
Metastasis | < 0.0001 | |||
No | 2559 (90.97%) | 242 (60.8%) | 251 (93.66%) | |
Yes | 254 (9.03%) | 156 (39.2%) | 17 (6.34%) | |
Tumor size | < 0.0001 | |||
≤ 5 cm | 1596 (56.74%) | 156 (39.2%) | 148 (55.22%) | |
> 5 cm | 680 (24.17%) | 157 (39.45%) | 57 (21.27%) | |
Unknow | 537 (19.09%) | 85 (21.36%) | 63 (23.51%) | |
Tumor number | 0.11 | |||
1 | 2557 (90.9%) | 350 (87.94%) | 224 (83.58%) | |
> 1 | 256 (9.1%) | 48 (12.06%) | 44 (16.42%) | |
T stage | < 0.0001 | |||
Tis | 146 (5.19%) | 3 (0.75%) | 11 (4.10%) | |
T1 | 904 (32.14%) | 58 (14.57%) | 92 (34.33%) | |
T2 | 521 (18.52%) | 53 (13.32%) | 56 (20.90%) | |
T3 | 921 (32.74%) | 159 (39.95%) | 85 (31.72) | |
T4 | 244 (22.86%) | 91 (22.86%) | 9 (3.36%) | |
Tx | 77 (2.74%) | 34 (8.54%) | 15 (5.6%) |